Nanostructure comprising peroxidase mimetics, glucose oxidases and particles with Photothermal effect

A nanostructure combining peroxidase-mimicking enzymes, glucose oxidase, and photothermal particles in a fucoidan-chitosan complex addresses the limitations of existing cancer treatments by enhancing efficacy through starvation and photothermal therapies, specifically targeting and killing cancer cells.

KR103046924B1Active Publication Date: 2026-11-10IND UNIV COOP FOUND HANYANG UNIV ERICA CAMPUS
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020240128670
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-09-24
Publication Date
2026-11-10
Estimated Expiration
2044-09-24

AI Technical Summary

Technical Problem

Existing cancer treatments, such as single anticancer therapies, suffer from low efficacy and significant side effects, while multimodal therapies face challenges like toxicity, low cell uptake, and efficacy concerns of nanomaterials.

Method used

A nanostructure comprising a peroxidase-mimicking enzyme, glucose oxidase, and particles with a photothermal effect, encapsulated in a fucoidan and chitosan complex, which synergistically induces starvation, catalytic, and photothermal therapies to target cancer cells.

Benefits of technology

The nanostructure effectively kills cancer cells by blocking glucose supply, generating reactive oxygen species, and inducing a photothermal effect, demonstrating enhanced anticancer efficacy with rapid absorption and minimal toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024103856362-PAT00002_ABST
    Figure 112024103856362-PAT00002_ABST
Patent Text Reader

Abstract

The nanostructure comprising the peroxidase-mimicking enzyme, glucose oxidase, and particles having a photothermal effect of the present application can be utilized as a pharmaceutical composition for the prevention or treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present application relates to a nanostructure comprising a peroxidase-mimicking enzyme, a glucose oxidase, and particles having a photothermal effect. Background Technology

[0002] Cancer is the leading cause of death in Korea and the second leading cause of death worldwide. Common treatment methods include surgical procedures, radiation therapy, and chemotherapy. However, existing single anticancer therapies have the disadvantage of relatively low anticancer efficacy despite concerns regarding serious drug side effects. Therefore, research is ongoing to develop multimodal therapies that combine two or more treatments to overcome these drawbacks and provide superior safety and efficacy, thereby creating synergy among various therapeutic approaches.

[0003] Among them are chemodynamic therapy (CDT), a treatment that induces harmful reactive oxygen species (ROS) inside cancer cells through the treatment of specific substances and causes internal imbalance, eventually leading to cell death; starvation therapy using glucose oxidase; and photothermal therapy (PTT), a treatment that leads to cell death through heat generated by particles oxidized by hydrogen peroxide produced during the process of the above treatments.

[0004] In addition, while treatments combining CDTs such as Fenton reaction and hypoxia-activated therapy with starvation therapy (ST) and PTT are attracting a lot of attention, there are still many factors to consider, such as the toxicity and side effects of nanomaterials, low cell uptake of metal-organic frameworks, and concerns regarding efficacy, which is why the introduction of nanomaterials for cancer treatment is still limited.

[0005] Accordingly, the inventors developed a nanostructure comprising a novel peroxidase-mimicking enzyme, glucose oxidase, and particles having a photothermal effect. Prior art literature

[0006] 10-2643240 The problem to be solved

[0007] The present application aims to provide a nanostructure with enhanced cancer treatment efficacy.

[0008] Another technical objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of cancer comprising the nanostructure.

[0009] Another technical objective of the present invention is to provide a method for manufacturing the nanostructure.

[0010] However, the technical problems that this application aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by a person skilled in the art from the description below. means of solving the problem

[0011] To solve the above problem, the present invention provides a nanostructure comprising a peroxidase-mimicking enzyme, a glucose oxidase, and a particle having a photothermal effect.

[0012] In one embodiment of the present invention, the nanostructure may have anticancer efficacy through a synergistic action via starvation therapy, catalytic therapy, and photothermal therapy.

[0013] As another embodiment of the present invention, cancer cells may be specifically killed by generating reactive oxygen species by the peroxidase-mimicking enzyme.

[0014] As another embodiment of the present invention, the glucose oxidase may block the supply of glucose to cancer cells while generating gluconic acid and hydrogen peroxide.

[0015] As another embodiment of the present invention, the peroxidase mimicking enzyme may comprise Prussian blue nanoenzyme.

[0016] As another embodiment of the present invention, the particle having the photothermal effect may comprise 3,3',5,5'-tetramethylbenzidine.

[0017] As another embodiment of the present invention, the nanostructure may be a fucoidan and chitosan complex that encapsulates the peroxidase-mimicking enzyme, the glucose oxidase, and the particles having the photothermal effect.

[0018] As another embodiment of the present invention, the nanostructure may be a crystalline structure with a size of 100 to 500 nm.

[0019] As another embodiment of the present invention, the zeta potential of the nanostructure may be 10 to 30 mV.

[0020] As one embodiment of the present invention, a pharmaceutical composition for cancer prevention or treatment comprising the nanostructure of claim 1 is provided.

[0021] As one embodiment of the present invention, a first solution prepared by mixing chitosan and acetic acid and adding hydrogen peroxide;

[0022] A second solution prepared by mixing a peroxidase-mimicking enzyme, glucose oxidase, and particles having a photothermal effect into a fucoidan solution;

[0023] A method for manufacturing a nanostructure, wherein the above-mentioned second solution is mixed with the first solution.

[0024] In another embodiment of the present invention, the first solution and the second solution may have the same pH.

[0025] As another embodiment of the present invention, the pH may be 6.0.

[0026] As another embodiment of the present invention, the volume ratio of the first solution and the second solution may be about 1:1 to 2 times.

[0027] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled expert in the art to which this invention pertains. In general, the nomenclature used herein is well known and commonly used in the art. Effects of the invention

[0028] The present invention relates to a nanostructure comprising a peroxidase-mimicking enzyme, a glucose oxidase, and particles having a photothermal effect, and a pharmaceutical composition for cancer prevention or treatment containing the same.

[0029] The present invention relates to a nanostructure having enhanced anticancer efficacy due to a series of continuous enzymatic / catalytic reactions resulting from the breakdown of glucose, which is significantly more abundant in cancer cells compared to normal cells, and exhibits enhanced anticancer efficacy through catalytic therapy by glucose oxidase and peroxidase-mimicking enzymes, starvation therapy, and photothermal therapy by particles having a photothermal effect.

[0030] Specifically, the nanostructure can specifically kill cancer cells while remaining very stable in normal cells by blocking the supply of glucose and generating reactive oxygen species.

[0031] In addition, by encapsulating the aforementioned particles in a fucoidan / chitosan complex, the problems of low absorption rate and slow reaction time associated with conventional metal-organic frameworks can be resolved.

[0032] Specifically, the fucoidan-chitosan complex-based anticancer agent of the present invention can be manufactured under conditions using water as a solvent, without involving organic synthesis processes or long-term extraction processes. Furthermore, it has the advantage of rapid absorption and requires a short time to confirm efficacy compared to metal-organic nano anticancer agents. Consequently, it has the effect of providing an effective anticancer agent in an efficient and economical manner. Brief explanation of the drawing

[0033] A brief description of each drawing is provided to help to better understand the drawings cited in the detailed description of the present application. Figure 1A is a schematic diagram showing the process of forming a nano-sized fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx) containing synthesized Prussian blue, glucose oxidase, and 3,3',5,5'-tetramethylbenzidine (TMB) simultaneously, and Figure 1B is a schematic diagram showing the mechanism of the process in which an anticancer effect occurs through the glucose oxidase, Prussian blue, and 3,3',5,5'-tetramethylbenzidine inside the nanostructure in a cancer cell environment. Figure 2 shows a transmission electron microscope (TEM) image of a prepared fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx). Figure 3 shows the DLS measurement results indicating the particle size of the prepared fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx). Figure 4 shows the zeta potential results representing the surface charge of the fabricated fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx). Figure 5 shows scanning transmission electron microscope (STEM) and elemental mapping images of a fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx) containing Prussian blue nanoenzyme, glucose oxidase, and 3,3',5,5'-tetramethylbenzidine. Figure 6A shows the results of measuring the oxidation of glucose by glucose oxidase contained in F / CS@TPGOx and the subsequent generation of hydrogen peroxide, the reduction of hydrogen peroxide by Prussian blue nanoenzyme mimicking peroxidase activity, the oxidation of TMB inside the complex and the resulting color change (OD652nm) using UV-Vis absorbance spectra, and the results of comparing the absorbance of a material irradiated with an 808nm laser and a material not irradiated with it. Figure 7 shows the results of measuring the UV-Vis absorbance spectrum according to the concentration of glucose, including the oxidation of glucose by glucose oxidase contained in F / CS@TPGOx and the subsequent generation of hydrogen peroxide, the reduction of hydrogen peroxide by Prussian blue nanoenzyme mimicking the activity of the glucose oxidase, the oxidation of TMB inside the complex and the resulting color change (OD652 nm). Figure 8A shows the results of infrared camera measurements of the oxidation of glucose and the subsequent generation of hydrogen peroxide caused by glucose oxidase contained in F / CS@TPGOx, the reduction of hydrogen peroxide caused by Prussian blue nanoenzymes mimicking peroxidase activity, the oxidation of TMB inside the nanostructure, and the photothermal effect resulting from laser treatment. A was measured according to glucose concentration, B according to the concentration of the complex, and C according to the laser intensity. Fig. 9A is a normal cell, a fibroblast (C3H 10 T 1 / 2 B shows the non-toxicity results of F / CS@TPGOx against ) and shows the anticancer effect results of F / CS@TPGOx against breast cancer cells (MDA MB-231). Figure 10 is a fluorescence microscope image showing the qualitative effects of the synthesized fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx) on breast cancer cells through live / dead staining. Figure 11 is a fluorescence microscope image showing the reactive oxygen species (ROS) formed inside breast cancer cells by the synthesized fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx) through DCFH-DA staining. Figure 12 illustrates the results of the anticancer effect of the synthesized fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx) in a Balb / c nude mouse lineage in which MDA MB-231 cells were carcinogenic. Figure 12 illustrates the non-toxic results of F / CS@TPGOx through changes in the body weight of the mice during the experimental period. Figure 13 shows the temperature change when F / CS@TPGOx is injected, a reaction time of 30 minutes is given, and then the injection site is irradiated with a 1 W / cm² laser for 10 minutes. Figure 13A is a graph and B is a photograph of a mouse. Figure 14A is a photograph of the cancer extracted after the experimental period. B is the result of tissue staining of the extracted cancer. Specific details for implementing the invention

[0034] In the present invention, the term “nanostructure” means a structure having at least one region or characteristic dimension (e.g., height, length, thickness, diameter, etc.) of less than 1 μm, and in some embodiments, the nanostructure has dimensions of less than about 500 nm, less than about 200 nm, less than about 100 nm, less than about 50 nm, less than about 20 nm, or less than about 10 nm. Typically, the region or characteristic dimension will be along the smallest axis of the structure. Examples of such structures include nanowires, nanorods, nanotubes, branched nanostructures, nanotetrapods, tripods, bipods, nanocrystals, nanodots, QDs, nanoparticles, etc. The nanostructures may be, for example, substantially crystalline, substantially monocrystalline, polycrystalline, amorphous, or a combination thereof.

[0036] As one embodiment of the present invention, a nanostructure comprising a peroxidase-mimicking enzyme, a glucose oxidase, and particles having a photothermal effect is provided.

[0037] In the present invention, the term "glucose oxidase (GOx)" refers to an enzyme that oxidizes glucose into gluconic acid, "peroxidase mimic enzyme" refers to an enzyme having peroxidase activity that effectively induces reactive oxygen species (ROS) under acidic conditions, and "particle having a photothermal effect" refers to a particle having the characteristic of absorbing light energy and then releasing it as heat energy.

[0038] Specifically, the nanostructure may have anticancer efficacy through synergistic action via starvation therapy, catalytic therapy, and photothermal therapy.

[0039] In addition, it may be possible to specifically kill cancer cells by generating reactive oxygen species through the above-mentioned peroxidase-mimicking enzyme.

[0040] In addition, the glucose oxidase may block the supply of glucose to cancer cells and produce gluconic acid and hydrogen peroxide.

[0041] The nanostructure of the present invention can block the supply of energy sources to cancer cells through glucose oxidation, act as a hydrogen peroxide catalyst through peroxidase-mimicking activity, generate harmful reactive oxygen species inside cancer cells, and induce a photothermal effect on hydrogen peroxide generated as a result of glucose oxidation, thereby inducing the death of target cancer cells through the corresponding sequential reaction.

[0042] The above nanostructure exhibits specific toxicity to cancer cells by blocking the supply of glucose, which is the energy source of cancer cells, by glucose oxidase in cancer cells, generating gluconic acid and hydrogen peroxide, and by gluconic acid reducing pH and hydrogen peroxide generating harmful reactive oxygen species inside cancer cells by peroxidase mimic enzymes.

[0043] As another embodiment of the present invention, the peroxidase mimic enzyme may comprise Prussian blue nanoenzymes (PBNPs).

[0044] As another embodiment of the present invention, the particles having the photothermal effect may comprise 3,3',5,5'-tetramethylbenzidine (TMB).

[0045] As another embodiment of the present invention, the nanostructure may be a fucoidan and chitosan complex that encapsulates the peroxidase-mimicking enzyme, the glucose oxidase, and the particles having the photothermal effect.

[0046] Since the above-mentioned fucoidan has cancer cell-specific binding ability, the nanostructure comprising the above-mentioned oxidase-mimicking enzyme, the above-mentioned glucose oxidase, and the above-mentioned particle having a photothermal effect is very stable in normal cells while being able to specifically kill cancer cells.

[0047] In addition, it is characterized by initiating a catalytic reaction under specific conditions of the tumor microenvironment (TME) (excess glucose, weakly acidic environment) by blocking the supply of glucose and generating reactive oxygen species, and exhibiting a photothermal effect through laser treatment.

[0048] In addition, the above nanostructure can stably store and deliver Prussian blue nanoenzyme, glucose oxidase, and TMB in normal cells, and can improve biocompatibility.

[0049] As another embodiment of the present invention, a pharmaceutical composition for cancer prevention or treatment comprising the nanostructure is provided.

[0050] In the present invention, the term "prevention" refers to any act of suppressing or delaying the occurrence, spread, or recurrence of cancer by administering a composition of the present invention, and the term "treatment" refers to any act of improving or beneficially altering the symptoms of cancer by administering a composition of the present invention.

[0051] In the present invention, the term "pharmaceutical composition" means prepared for the purpose of preventing or treating a disease, and the pharmaceutical composition is not particularly limited in its formulation, route of administration, and method of administration as long as it exhibits the effects of the present invention, and the pharmaceutical composition of the present invention may additionally include known anticancer agents in addition to the nanostructures of the present invention and may be used in combination with other known treatments for the treatment of these diseases.

[0053] As another embodiment of the present invention, a first solution prepared by mixing chitosan and acetic acid and adding hydrogen peroxide;

[0054] A second solution prepared by mixing a peroxidase-mimicking enzyme, glucose oxidase, and particles having a photothermal effect into a fucoidan solution;

[0055] A method for manufacturing a nanostructure, wherein the above-mentioned second solution is mixed with the first solution.

[0056] In another embodiment of the present invention, the first solution and the second solution may have the same pH.

[0057] As another embodiment of the present invention, the pH may be 6.0.

[0058] As another embodiment of the present invention, the volume ratio of the first solution and the second solution may be about 1:1 to 2 times.

[0059] Within the above range, the formation of nanostructured particles is easy, and active ingredients can be easily captured.

[0060] In addition, since the above nanostructure can be manufactured using water as a solvent without requiring an organic synthesis process or a long extraction process, a pharmaceutical composition for cancer prevention or treatment containing it can be provided efficiently and economically.

[0062] The present invention is capable of various modifications and may have various embodiments. Specific embodiments are illustrated in the drawings and described in detail in the detailed description below. However, this is not intended to limit the present invention to specific embodiments, and it should be understood that it includes all modifications, equivalents, and substitutions that fall within the spirit and scope of the present invention. In describing the present invention, detailed descriptions of related prior art are omitted if it is determined that such detailed descriptions may obscure the essence of the present invention.

[0064] Preparation Example 1: Synthesis of a Fucoidan / Chitosan Complex-Based Anticancer Agent (F / CS@TPGOx) Containing Prussian Blue Nanoenzyme, Glucose Oxidase, and TMB

[0065] Figure 1A is a schematic diagram showing the process of forming a nano-sized fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx) containing synthesized Prussian blue, glucose oxidase, and 3,3',5,5'-tetramethylbenzidine simultaneously, and Figure 1B is a schematic diagram showing the mechanism of the process in which an anticancer effect occurs through glucose oxidase, Prussian blue, and 3,3',5,5'-tetramethylbenzidine inside the complex in a cancer cell environment.

[0067] 1.1. Synthesis of Prussian Blue Nanoenzyme (PB)

[0068] 20 mL of aqueous solution A containing 10 mM FeCl3·6H2O and 5 mmol of citric acid, and 20 mL of aqueous solution B containing 10 mM K4[Fe(CN)6] and 5 mmol of citric acid were heated sufficiently to 60°C. Aqueous solution B was added all at once to the flask containing solution A and reacted for 1 minute, after which it was cooled at room temperature for 5 minutes. An equal amount of acetone was added to induce precipitation, followed by centrifugation at 13,000 rpm for 25 minutes. The supernatant was discarded, and ethanol and water were added sequentially to perform two more washes. In the final step, a certain amount of triple-distilled water was added, and the synthesized Prussian blue nanoenzyme (PB) was evenly distributed through sufficient ultrasonic cleaning. The concentration of the synthesized PB was measured by inductively coupled plasma (ICP) analysis.

[0070] 1.2. Synthesis of Fucoidan / Chitosan Complex and Capture of Prussian Blue Nanoenzyme, Glucose Oxidase, and TMB

[0071] For the hydrolysis of chitosan, dissolve it in 1% acetic acid to a final concentration of 20 g / L. To prepare the solution, add 30% hydrogen peroxide to the chitosan / acetic acid aqueous solution and mix to a final concentration of 2%. Then, stir at room temperature for 24 hours. The reaction is terminated by adding 5% NaOH. Prepare a fucoidan solution at a concentration of 5 mg / mL and a pH of 6.0, and a chitosan / acetic acid solution at a concentration of 5 mg / mL and a pH of 6.0. Next, mix 355 μL of the fucoidan solution with 26.4 μL of PBNP (0.9 μg / mL), 10 mg of glucose oxidase, and 166 μL of 200 mM TMB. Mix the prepared fucoidan mixture with 710 μL of chitosan / acetic acid at 160 rpm for 3 minutes. After centrifuging the sample at 8,000 rpm for 10 minutes, store it in 500 ml distilled water.

[0073] Experimental Example 1: Confirmation of Anticancer Nanostructure Properties of F / CS@TPGOx

[0074] To evaluate whether the fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx) synthesized in Preparation Example 1 above was well formed and to assess its physical properties, TEM, DLS, Zeta potential, and STEM analyses were performed, and the results obtained are shown in Figures 2 to 5 along with photographs.

[0075] Figure 2 shows a transmission electron microscope (TEM) image of the synthesized fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx). When reacted for 3 minutes, a crystalline structure of approximately 200–300 nm in size was formed. The size of the nanostructures matched the size confirmed by dynamic light scattering (DLS) measurements (Figure 3). In addition, zeta potential measurements, which indicate surface charge, confirmed that chitosan and F / CS@TPGOx had positive surface charge values, while fucoidan had negative surface charge values ​​(Figure 4). Figure 5 shows a scanning transmission electron microscope (STEM) image and an elemental mapping image of the fucoidan / chitosan complex-based anticancer agent (F / CS@TPGOx) containing Prussian blue nanoenzyme, glucose oxidase, and TMB. Through this, it was confirmed that the two target active substances were well encapsulated within the fucoidan / chitosan complex.

[0077] Experimental Example 2: Evaluation of Catalytic Activity of F / CS@TPGOx Anticancer Nanostructures

[0078] UV-Vis absorbance measurements were performed to evaluate the catalytic activity of the F / CS@TPGOx anticancer nanostructure synthesized in Preparation Example 1 above, and the results obtained are shown in Figures 6 and 7.

[0079] Figure 6 shows the results of measuring the reduction of hydrogen peroxide, oxidation of TMB inside the complex, and resulting color change (OD 652 nm) by glucose oxidase contained in the F / CS@TPGOx anticancer nanostructure and Prussian blue nanoenzyme mimicking peroxidase activity, using UV-Vis absorbance spectra. A 40 mM aqueous glucose solution containing 800 μg / ml F / CS@TPGOx was reacted in a pH 5 buffer. After satisfying the final volume of 100 and reacting at room temperature for 10 minutes, a laser was irradiated for 10 minutes on the group requiring laser effect. The group not treated with the laser was left at room temperature for 10 minutes after the reaction. Subsequently, the absorbance of the oxidized TMB, which had turned blue (OD 652 nm), was measured.

[0080] Figure 7 shows the results of measuring the reduction of hydrogen peroxide, oxidation of TMB inside the complex, and the resulting color change (OD652nm) using UV-Vis absorbance spectra, caused by glucose oxidase contained in the anticancer nanostructure and Prussian blue nanoenzyme mimicking peroxidase activity. It can be seen that the intensity of the OD652nm of the oxidized TMB inside the complex increases in proportion to the concentration of glucose. This indicates a reaction in which the oxidation of glucose and the generation of hydrogen peroxide caused by GOx in F / CS@TPGOx, followed by the reduction of hydrogen peroxide and the oxidation of TMB inside the complex caused by PB in F / CS@TPGOx, occurred sequentially, confirming that a continuous enzymatic / catalytic reaction took place in the presence of glucose.

[0082] Experimental Example 3: Evaluation of Photothermal Effect

[0083] Glucose oxidase within the complex initiates glucose decomposition to produce glucose acid and H₂O₂, after which TMB is oxidized. The oxidized TMB then absorbs light from an 808 laser to generate heat. The photothermal effect was investigated according to wattage (W), glucose concentration, and F / CS@TPGOx concentration. In Figures 8A and 8B, a significant temperature rise was observed under laser irradiation at an intensity of 1 W / cm² when the concentrations of glucose and F / CS@TPGOx were different, indicating that the presence of F / CS@TPGOx can effectively convert NIR light energy into heat. When 40 mM glucose was added to 800 μg / ml F / CS@TPGOx and reacted for 10 minutes, followed by laser irradiation for 5 minutes, a temperature rise of up to 76°C was observed. According to Figure 8B, the PTT effect of this substance was found to be proportional to the glucose concentration. Figure 8C confirmed that the solution temperature under the same conditions increased proportionally to W.

[0085] Experimental Example 4: Cytotoxicity Evaluation (In vitro assay)

[0086] To confirm the toxicity and anticancer effects of F / CS@TPGOx, fibroblasts (C3H 10 T 1 / 2 Cytotoxicity was evaluated using WST-1 with ) and breast cancer cells (MDA MB-231).

[0087] Fig. 9A is a normal cell, a fibroblast (C3H 10 T 1 / 2 B shows the non-toxicity results of F / CS@TPGOx against ) and B shows the anticancer effect results of F / CS@TPGOx against breast cancer cells (MDA MB-231).

[0088] According to Fig. 9A, C3H, which is a normal cell 10 T 1 / 2When used, both the F / CS@TPGOx monotherapy group and the F / CS@TPGOx+laser group did not induce normal cell death compared to cancer cells at concentrations of 4 to 20 μg / ml. According to Figure 9B, when MDA MB-231 cancer cells were used, the F / CS@TPGOx monotherapy group induced 50% cancer cell death within 2 hours at a concentration of 12 μg / ml.

[0089] The F / CS@TPGOx+laser treatment group showed a 60% reduction in cell viability at a concentration of 12 μg / ml. Additionally, both of the aforementioned groups were shown to reduce cell viability by 80% within 4 hours at concentrations ranging from 4 to 20 μg / ml. These results indicate that while F / CS@TPGOx is biocompatible with normal cells, it can induce apoptosis in cancer cells through synergistic effects.

[0090] Furthermore, the difference in cell death rates induced by laser irradiation at a concentration of 12 μg / ml indicates that the photothermal effect of TMB aids in cancer cell death upon laser treatment. In conclusion, laser treatment of F / CS@TPGOx exhibited a greater cancer cell death effect due to enhanced catalytic activity.

[0091] Figure 10 is a fluorescence microscope image showing the qualitative effects of the synthesized F / CS@TPGOx alone and F / CS@TPGOx+laser groups on breast cancer cells through live / dead staining. It was qualitatively shown through fluorescence staining that the F / CS@TPGOx alone group and especially the F / CS@TPGOx+laser group showed the greatest killing effect compared to the control group, which showed low toxicity to breast cancer cells.

[0092] Figure 11A is a fluorescence microscope image showing the qualitative results of reactive oxygen species (ROS) formed inside breast cancer cells in the synthesized F / CS@TPGOx alone and F / CS@TPGOx+laser groups via DCFH-DA staining. Fluorescent staining qualitatively indicated that the highest amount of ROS was formed in the F / CS@TPGOx alone group and, in particular, the F / CS@TPGOx+laser group, compared to the control group which exhibited low toxicity to breast cancer cells. Figure 11B quantitatively showed this, revealing that more ROS is generated within the same time period when treated with a laser. This demonstrates that the photothermal effect using TMB aids the catalytic activity of Prussian enzymes and glucose enzymes, thereby killing cancer cells.

[0094] Experimental Example 5: Animal Toxicity Evaluation (In vivo experiment)

[0095] Figure 12A was conducted to suggest non-toxic results for the F / CS@TPGOx alone and F / CS@TPGOx+laser groups. Throughout the entire treatment course, no mice in either group showed a noticeable change in body weight, which demonstrates that F / CS@TPGOx administration does not affect the growth of mice and is not highly toxic to mice.

[0096] Figure 13 observes the temperature changes of the laser group. A shows the temperature changes of the mice over 10 minutes. 50 μl each of PBS (control) and F / CS@TPGOx were injected, and after 30 minutes, the tumor site was irradiated with a laser for 10 minutes at an output density of 1 W / cm². The temperature of the group treated with the laser on F / CS@TPGOx rose to 52 to 53°C, which is an effective temperature for cancer treatment. Figure 13B is an image of the temperature changes of the mice at this time. Consequently, it indicates that a photothermal effect caused by the laser occurred due to a chain reaction within the complex.

[0098] Figure 14A shows images of tumors excised for histological analysis after 14 days of mouse treatment. The results showed a significant reduction in tumors in the F / CS@TPGOx and F / CS@TPGOx + laser groups compared to the control and control+laser groups. In particular, the F / CS@TPGOx + laser group demonstrated enhanced therapeutic effects in in vivo cancer treatment compared to other therapies, as tumors disappeared in 4 out of 5 mice. This enhanced efficacy indicates a synergistic effect of ST / CDT / PTT. Figure 14B shows the results of the histological analysis of the tumor tissues. H&E staining revealed that most tumor cells exhibited apoptotic / necrotic characteristics after F / CS@TPGOx alone and F / CS@TPGOx + laser treatment. These features include cytoplasmic vacuoles and cell membrane rupture. In addition, when the expression of the Ki-67 protein, which acts as a marker for cancer cell proliferation, was investigated by immunohistochemical staining, the lowest proportion of Ki-67-positive cells was observed in the F / CS@TPGOx and F / CS@TPGOx + laser groups, demonstrating that treatment based on F / CS@TPGOx has an inhibitory effect on cancer cell proliferation.

[0100] Foregoing, specific parts of the contents of this application have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of this application. Accordingly, the actual scope of this application is defined by the appended claims and their equivalents.

Claims

Claim 1 Nanostructures comprising Prussian blue nanoenzyme, glucose oxidase, and 3,3',5,5'-tetramethylbenzidine. Claim 2 A nanostructure according to claim 1, wherein the nanostructure has anti-breast cancer efficacy through synergistic action via starvation therapy, catalytic therapy, and photothermal therapy. Claim 3 A nanostructure according to claim 1, which specifically kills breast cancer cells by generating reactive oxygen species through the peroxidase-mimicking enzyme. Claim 4 A nanostructure according to claim 1, wherein the glucose oxidase blocks the supply of glucose to breast cancer cells while generating gluconic acid and hydrogen peroxide. Claim 5 delete Claim 6 delete Claim 7 In claim 1, the nanostructure is a nanostructure in which a fucoidan and chitosan complex encapsulates particles having the Prussian blue nanoenzyme, the glucose oxidase, and the 3,3',5,5'-tetramethylbenzidine. Claim 8 A nanostructure according to claim 1, wherein the nanostructure is a crystalline structure with a size of 100 to 500 nm. Claim 9 A nanostructure according to claim 1, wherein the zeta potential of the nanostructure is 10 to 30 mV. Claim 10 A pharmaceutical composition for the prevention or treatment of breast cancer comprising the nanostructure of claim 1. Claim 11 A method for manufacturing a nanostructure, comprising: a first solution prepared by mixing chitosan and acetic acid and adding hydrogen peroxide; a second solution prepared by mixing Prussian blue enzyme, glucose oxidase, and 3,3',5,5'-tetramethylbenzidine into a fucoidan solution; and a second solution prepared by mixing the second solution with the first solution. Claim 12 A method for manufacturing a nanostructure according to claim 11, wherein the first solution and the second solution have the same pH. Claim 13 A method for manufacturing a nanostructure according to claim 12, wherein the pH is 6.

0. Claim 14 A method for manufacturing a nanostructure according to claim 11, wherein the volume ratio of the first solution and the second solution is 1:1 to 2 times.

Citation Information

Patent Citations

  • Simvastatin / manganese bonded hollow mesoporous Prussian blue / glucose oxidase nano preparation as well as preparation method and application thereof

    CN115282291A

  • Nanostructure comprising metal organic frameworks, glucose oxidases, and peroxidase mimetics, and use thereof

    KR102643240B1